Should the Food and Drug Administration Limit Placebo-Controlled Trials? by Max Goodman, Connor Pedersen

“…While the FDA believes there may be methodologically compelling reasons to utilize PCTs, they have demonstrated a lack of judgment necessary to balance the gains against their inherent losses, requiring the public to step in. CONCLUSION Based on the ambiguous bioethical guidelines that the FDA follows, and the moral justifications described in this paper, its preference of PCTs is unethical. …”
Get full text